期刊文献+

CYP2C19和ABCB1基因多态性及其在冠心病患者中差异性分布 被引量:3

下载PDF
导出
摘要 目的探讨影响氯吡格雷转运和代谢相关基因多态性分布规律。方法选取皖南医学院弋矶山医院2015年7月-2016年7月需要接受氯吡格雷治疗的冠心病患者120例,采用原位杂交荧光染色分析技术检测患者CYP2C19*2、CYP2C19*3和ABCB1 3435C>T基因型。结果 CYP2C19*2、CYP2C19*3和ABCB1 3435C>T突变频率分别为21.25%、12.08%和36.25%。男性ABCB1 3435C>T突变率高于女性(P=0.022)。结论 CYP2C19和ABCB1基因检测为氯吡格雷个体化治疗提供技术支持,但仍需进一步验证。
出处 《临床合理用药杂志》 2018年第25期131-132,134,共3页 Chinese Journal of Clinical Rational Drug Use
基金 安徽省科技攻关项目(1604a0802097) 皖南医学院中青年项目自然科学类(WK2016F10 WK2017F14) 皖南医学院弋矶山医院三新项目(Y1604)
  • 相关文献

参考文献9

二级参考文献113

  • 1Anderson JL,Adams CD,Antman EM,et al.ACC/AHA 2007guidelines for the management of patients with unstableangina/non-ST-Elevation myocardial infarction:a report of theAmerican College of Cardiology/American Heart Association TaskForce on Practice Guidelines(Writing Committee to Revise the 2002Guidelines for the Management of Patients With UnstableAngina/Non-ST-Elevation Myocardial Infarction)developed incollaboration with the American College of Emergency Physicians,the Society for Cardiovascular Angiography and Interventions,andthe Society of Thoracic Surgeons endorsed by the AmericanAssociation of Cardiovascular and Pulmonary Rehabilitation and theSociety for Academic Emergency Medicine[J].J Am Coll Cardiol,2007,50(7):e1-e157.
  • 2Steinhubl SR,Berger PB,Mann JT,et al.Early and sustained dual oralantiplatelet therapy following percutaneous coronary intervention:arandomized controlled trial[J].JAMA,2002,288(19):2411-2420.
  • 3Yusuf S,Zhao F,Mehta SR,et al.Effects of clopidogrel in addition toaspirin in patients with acute coronary syndromes without ST-seg-ment elevation[J].N Engl J Med,2001,345(7):494-502.
  • 4Serebruany VL,Steinhubl SR,Berger PB,et al.Variability in plateletresponsiveness to clopidogrel among 544 individuals[J].J Am CollCardiol,2005,45(2):246-251.
  • 5Sweeny JM,Gorog DA,Fuster V.Antiplatelet drug'resistance'.Part 1:mechanisms and clinical measurements[J].Nat Rev Cardiol,2009,6(4):273-282.
  • 6Gurbel PA,Bliden KP,Hiatt BL,et al.Clopidogrel for coronarystenting:response variability,drug resistance,and the effect ofpretreatment platelet reactivity[J].Circulation,2003,107(23):2908-2913.
  • 7Angiolillo DJ,Fernandez-Ortiz A,Bernardo E,et al.PlA polymorp-hism and platelet reactivity following clopidogrel loading dose inpatients undergoing coronary stent implantation[J].Blood CoagulFibrinolysis,2004,15(1):89-93.
  • 8Taubert D,von Beckerath N,Grimberg G,et al.Impact of P-glycopr-otein on clopidogrel absorption[J].Clin Pharmacol Ther,2006,80(5):486-501.
  • 9Mega JL,Close SL,Wiviott SD,et al.Genetic variants in ABCB1 andCYP2C19 and cardiovascular outcomes after treatment with clopid-ogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogeneticanalysis[J].Lancet,2010,376(9749):1312-1319.
  • 10Marcucci R,Gori AM,Paniccia R,et al.Cardiovascular death andnonfatal myocardial infarction in acute coronary syndrome patientsreceiving coronary stenting are predicted by residual platelet react-ivity to ADP detected by a point-of-care assay:a 12-month follow-up[J].Circulation,2009,119(2):237-242.

共引文献102

同被引文献41

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部